Research
Hormonal
Obesity significantly increases the susceptibility to type 2 diabetes, with risk increasing exponentially with higher BMI levels.
If you are overweight, your risk of developing type 2 diabetes is exponentially higher than if you were at a healthy weight. This risk is not linear; higher BMI levels correspond to dramatically higher susceptibility. Weight management is the most effective way to mitigate this specific risk.
GoodSupportsHIGH confidence
The susceptibility of diabetes is 80 times greater among obese adults than nonobese. Professor Sir George Alberti... has stated that those with a BMI of 35 have 'a 92-fold increase in the risk of diabetes' compared with those with a BMI of 22[38].
Why this rating
Cites expert statements and large-scale projections, though specific mechanistic trials are not detailed in this review.
Source
The rising prevalence of obesity: part A: impact on public health
Maliha Agha et al. · International Journal of Surgery Oncology · 2017
DOI 10.1097/ij9.0000000000000017
narrative_reviewCited 351×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity (BMI ≥ 30 kg/m²) is a primary driver of increased mortality risk, with relative risk of death increasing in a nonlinear manner as BMI rises.Good
- Obesity is a major risk factor for coronary heart disease (CHD), with susceptibility increasing 2-3 times in obese adults.Good
- Obesity is a significant risk factor for various cancers, with obese adults being 40% more likely to die from cancer than non-obese individuals.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →